There's no point trying to write any reason for most of the declines so I'll just list them. Suffice to say there is no Share of the Week as everything was shit.
JLP:Jubilee Metals was the biggest faller, losing 24% after predictably uninspiring results and despite good news on the waste dump project at the end of the week. Needless to say I bought some more.
IPX:Impax Asset Management dropped 20%.
ATYM:Atalaya Mining dropped 17%.
POLR:Polar Capital dropped 16%.
ASHM:Ashmore Group and FOUR:4imprint dropped 15%.
CWR:Ceres Power dropped 14%.
BHP:BHP Group dropped 13%.
CAML:Central Asia Metals, IHP:Integrafin and PAGE:Pagegroup dropped 12%.
ALPH:Alpha Group and PAF:Pan African Resources dropped 11% so even gold miners weren't spared.
RIO:Rio Tinto dropped 10%.
AJB:AJ Bell, APAX:Apax Global Alpha and FDM:FDM Group dropped 8%.
GAW:Games Workshop and WHR:Warehouse REIT dropped 7%.
BPM:BP Marsh & Partners and OPTI:Optibiotix dropped 6%.
CORE:Solidcore Resources, GSK:GSK and III:3i Group dropped 5%.
What a shit show!
Here's the ISA and shares portfolio after week 36 of year 10.
Weekly Change | |||
Cash | £112.02 | +£63.93 | |
Portfolio cost | £114,352.47 | +£0 | |
Portfolio sell value (bid price-commission) | £41,588.27 | (-63.6%) | -£5,056.25 |
Potential profits | £283.99 | +£0 | |
Yr 10 Dividends | £126.70 | +£17.47 | |
Yr 10 Interest | £1.06 | +£0.21 | |
Yr 10 Profit from sales | £327.55 | +£0 | |
Yr 10 proj avg monthly profit | £46.40 | (0.7%) | +£0.39 |
Total Dividends | £12,434.65 | +£17.47 | |
Total Interest | £7.86 | +£0.21 | |
Total Profit from sales | £17,602.85 | +£0 | |
Average monthly cash profit | £253.70 | (3.6%) | -£0.39 |
(Sold stocks profit + Dividends - Fees / Months) | |||
Compound performance | 35% | +0% |
I got a £17 dividend from ASHM:Ashmore Group which means I've had 14% return from them in dividends now. Shame they are down 53%. Cash went up a bit too, as I added £50 to my ISA before the end of the tax year to ensure fees are covered for next year. SBTX:SkinBioTherapeutix didn't change price so potential profits remain the same. That was the highlight of the whole week.
Too depressed for any chart commentary this week.
The SIPP looks like this after week 488 overall and week 20 of year 10.
Weekly Change | ||||
Cash | £338.44 | +£68.23 | ||
Portfolio cost | £128,954.22 | +£2,697.17 | ||
Portfolio sell value (bid price - commission) | £63,543.71 | (-50.7%) | -£6,926.50 | |
Potential profits | £3,252.13 | -£937.04 | ||
Yr 10 Dividends | £573.51 | +£31.35 | ||
Yr 10 Interest | £2.01 | +£0.71 | ||
Yr 10 Profit from sales | £2,375.87 | +£0 | ||
Yr 10 proj avg monthly profit | £618.29 | (8.7%) | -£29.03 | |
Total Dividends | £16,690.16 | +£31.35 | ||
Total Interest | £14.91 | +£0.71 | ||
Total Profit from sales | £19,383.81 | +£0 | ||
Average monthly cash profit | £307.33 | (4.3%) | -£0.49 | |
(Sold stocks profit + Dividends - Fees / Months) | ||||
Compound performance | 40% | -2% |
My £2,200 pension transfer came through and I also added £300 to go with recent tax relief and dividends. I got £31 dividend from APAX:Apax Global Alpha which means I've had 17% return from these but they are down 42%. Potential profits were hammered by £931 across the board and the drop in portfolio value was much worse than the ISA.
I bought 17,618 shares in JLP:Jubilee Metals after the large waste dump news at 2.9799p costing £530 taking my SIPP holding to 269,278, all of which will be sold as soon as they stop being rubbish.
I carried out my plan with the pension transfer and bought 23 shares in RIO:Rio Tinto at 4566.5p costing £1,067.50 and I also bought 352 shares in IHP:Integrafin at 307.474p costing £1,099.67. Both plummeted on Thursday and Friday so I shouldn't have bothered.
Well, that's a week I'd like to forget in a hurry. Will there be any recovery next week or will it get even worse?
Well, that's a week I'd like to forget in a hurry. Will there be any recovery next week or will it get even worse?
There's intrigue on 9th April when Boots launch a new formula of their popular No.7 brand. On their website it says the new formula is in collaboration with Manchester University, which is where SBTX:SkinBioTherapeutics came from, and Croda are due to launch their new lysate this month. Is it too much to hope for that SBTX is in the new No.7? We'll find out on Wednesday.